Viracta Therapeutics Stock Forum

$Viracta Therapeutics(VIRX.US)$ in game for 1.3+ ride

$Viracta Therapeutics(VIRX.US)$ Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and maintains $13 price target.

$Viracta Therapeutics(VIRX.US)$ Viracta Therapeutics Announces Positive Topline Nana-Val Results From Stage 1 of the Naval-1 Trial in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive (Ebv+) Peripheral T-Cell Lymphoma

📣 Ahead of AACR24, which starts this Friday, 🔬
here are 6 cancer readouts to watch this quarter:
$ImmunityBio(IBRX.US)$ : Anktiva ▻ PDUFA ▻ Bladder CA
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib ▻ PDUFA ▻ Glioma
$GlycoMimetics(GLYC.US)$ : Uproleselan ▻ Ph3 ▻ AML
$FibroGen(FGEN.US)$ : Pamrevlumab ▻ Ph3 ▻ Pancreatic CA
$Viracta Therapeutics(VIRX.US)$ : Nana-val ▻ Ph3 ▻ Lymphoma

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$Hutchmed (China)(HCM.US)$  Phase 3
$Viracta Therapeutics(VIRX.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Marinus Pharmaceuticals(MRNS.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3...

$Viracta Therapeutics(VIRX.US)$Moomoo 24/7· 1 min ago
Viracta Therapeutics Says FDA Granted Orphan Drug Designation To Nana-val For Treatment Of Nasopharyngeal Carcinoma

$Viracta Therapeutics(VIRX.US)$ RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)
RBC Capital analyst Gregory Renzamaintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41.
According to TipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA...

$Viracta Therapeutics(VIRX.US)$SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that additional data from the Phase 1b/2 clinical trial of Nana-val (nanatinostat in combination with valganciclovir) in patients with recurrent or metastatic (R/M) Epstein-Barr virus-positive (EBV+) nasopharyngeal carcino...